BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...company Handl Therapeutics B.V. UCB also entered an R&D deal with University of Florida spinout Lacerta Therapeutics Inc....
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...developing gene therapies for cardiomyopathy and multiple sclerosis. It is also partnered with UF spinout Lacerta Therapeutics Inc....
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...sclerosis; a deal with Lysogene S.A. (Euronext:LYS) for mucopolysaccharidosis Type IIIa; and a collaboration with Lacerta Therapeutics Inc....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A. (Euronext:LYS) and Lacerta Therapeutics Inc....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A. (Euronext:LYS) and Lacerta Therapeutics Inc....
BioCentury | Aug 10, 2018
Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

...NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc....
...by FactSet. Lacerta Therapeutics Inc., Alachua, Fla. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Gene/Cell therapy Elizabeth S. Eaton Lacerta Therapeutics Inc. Sarepta...
BioCentury | Aug 8, 2018
Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

...NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc....
...when it announced the deal and earnings. Consensus figures provided by FactSet. Elizabeth S. Eaton AAVrh74.MHCK7.micro-Dystrophin Sarepta Therapeutics Inc. Dystrophin Lacerta Therapeutics Inc....
Items per page:
1 - 7 of 7
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...company Handl Therapeutics B.V. UCB also entered an R&D deal with University of Florida spinout Lacerta Therapeutics Inc....
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...developing gene therapies for cardiomyopathy and multiple sclerosis. It is also partnered with UF spinout Lacerta Therapeutics Inc....
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...sclerosis; a deal with Lysogene S.A. (Euronext:LYS) for mucopolysaccharidosis Type IIIa; and a collaboration with Lacerta Therapeutics Inc....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A. (Euronext:LYS) and Lacerta Therapeutics Inc....
BioCentury | Nov 9, 2018
Financial News

Sarepta collects half a billion in follow-on

...Sarepta to build out its gene therapy pipeline, including partnerships with Lysogene S.A. (Euronext:LYS) and Lacerta Therapeutics Inc....
BioCentury | Aug 10, 2018
Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

...NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc....
...by FactSet. Lacerta Therapeutics Inc., Alachua, Fla. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Business: Gene/Cell therapy Elizabeth S. Eaton Lacerta Therapeutics Inc. Sarepta...
BioCentury | Aug 8, 2018
Company News

Sarepta bolsters gene therapy pipeline through deal with Lacerta

...NASDAQ:SRPT) gained exclusive rights to an undisclosed preclinical gene therapy to treat Pompe disease from Lacerta Therapeutics Inc....
...when it announced the deal and earnings. Consensus figures provided by FactSet. Elizabeth S. Eaton AAVrh74.MHCK7.micro-Dystrophin Sarepta Therapeutics Inc. Dystrophin Lacerta Therapeutics Inc....
Items per page:
1 - 7 of 7